Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiac Disease Vascular Diseases | Behavioral: Prebooking Behavioral: Pictured invitation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 5000 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Intervention Model Description: | 2 x factorial design regarding attendance rate to cardiovacular screening |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | Fighting Social Inequality in Cardiovascular Health I |
Actual Study Start Date : | August 1, 2017 |
Actual Primary Completion Date : | March 31, 2019 |
Actual Study Completion Date : | March 31, 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Prebooking
Participants randomised to this arm receives a prebooked appointment to screening
|
Behavioral: Prebooking
Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Behavioral: Pictured invitation Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
|
Placebo Comparator: Web based booking
Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
|
Behavioral: Prebooking
Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Behavioral: Pictured invitation Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
|
Active Comparator: Pictured invitation
Participants randomised to this arm receives a pictured invitation to screening
|
Behavioral: Prebooking
Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Behavioral: Pictured invitation Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
|
Placebo Comparator: Texted invitation
Participants randomised to this arm receives a classical texted invitation to screening
|
Behavioral: Prebooking
Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Behavioral: Pictured invitation Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
|
Ages Eligible for Study: | 60 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |
Nykøbing Falster Sygehus | |
Nykøbing Falster, Denmark, 4800 | |
Odense University Hospital | |
Odense, Denmark, 5000 | |
Region Hospital Silkeborg | |
Silkeborg, Denmark, 8600 | |
Svendborg Sygehus | |
Svendborg, Denmark, 5700 | |
Vejle Hospital | |
Vejle, Denmark, 7100 |
Principal Investigator: | Jes S Lindholt | Odense University Hospital |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | May 9, 2019 | ||||
First Posted Date ICMJE | May 13, 2019 | ||||
Last Update Posted Date | May 14, 2019 | ||||
Actual Study Start Date ICMJE | August 1, 2017 | ||||
Actual Primary Completion Date | March 31, 2019 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Attendance rate to screening [ Time Frame: 6 months ] The proportion of invited attending screening
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
Quality of Life of invitation to screening [ Time Frame: 6 months ] Quality of life measured by EurQol 5D
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Fighting Social Inequality in Cardiovascular Health I | ||||
Official Title ICMJE | Fighting Social Inequality in Cardiovascular Health I | ||||
Brief Summary | This study attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease (CVD) among people with low social status | ||||
Detailed Description |
Background Although CVDs have decreased, they are still among the most predominant cause of morbidity and mortality in the western world, incl. Denmark, where about 420,000 people have recognized CVD symptoms. Due to an aging population, the decline has not reduced CVD admissions and healthcare costs. In Denmark, the CVD related hospital admission costs are DKK 4.6 billion and the pharmaceutical cost DKK 2.4 billion. The Danish National Board of Health has reported that CVD carries the second largest socioeconomic difference in burden of disease. Unfortunately, population-based health checks and screening for risk factors has proven not efficient. Consequently, screening of asymptomatic CVD is discussed intensively. In the investigators first unique CVD screening RCT (2008-11), the VIVA trial, they randomized more than 50.000 65-74 year old men for population-based ultrasound screening for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD) and hypertension. In case of positive finding, preventive medical actions were initiated. A significant reduction in overall mortality by 7% after 5 years was observed (paper submitted). Using a non-contrast CT scan, instead of the ultrasound based screening approach, has the opportunity to identify aneurysms in the entire aortic, coronary artery calcification (CAC) and arterial fibrillation, so individualized risk assessment and initiation of preventive actions on those with sign of early asymptomatic CVD is possible. The investigators therefore initiated a second trial (DANCAVAS) in 2014 randomizing 45.000 65-74 year old men with the potential of a huge beneficial effect on health, quality of life (QoL) and survival. However, screening is impaired by lower social class, and adherence to initiated prevention could be impacted as well. Consequently, they want to conduct a third RCT (FISICH) to test a number of add-ons to screening that potentially balance the benefits across socio economic groups. The perspective is to establish a clear decision foundation for public health care policy incl. benefits, cost effectiveness and impact on social inequality of alternative variants of population screening for CVD. Hypotheses The primary hypothesis is that an extensive circulatory screening and intervention programme reduces social inequality in cardiovascular health and fulfills the WHO criteria for screening. However, this reduction can be even more pronounced, if factors reducing the social selection to attend screening and adherence to preventive actions initiated are identified. Aims The aims are to
Materials and methods In FISICH-I 20.000 60-64 year old men are randomized to the control group, while another 5.000 are randomized to the screening and intervention program for CAC, aortic and iliac aneurysms, atrial fibrillation, PAD, hypertension, diabetes and hypercholesterolaemia. There is no exclusion criteria. The screening setup is similar to DANCAVAS:
Follow-up visit after screening If the CAC is above the median or if an aneurism of peripheral arterial disease are detected the participant is informed of the finding and its implications at a follow-up visit. At this visit, the patient will be recommended suitable prophylactic measures, including smoking cessation, walking/exercise, a lowfat diet. Additionally to start treatment with aspirin 75 mg/day and atorvastatin 40 mg/day. If an aneurism is large the patient is referred vascular surgical assessment for the repair. Otherwise, an annual check-up of the aneurism including a CT scan will be offered. If no positive findings (CAC above the median, aneurysm or PAD) are detected, the participants will be informed of the findings by e-mail or ordinary post as preferred. Independent of the above findings, the patients will be encouraged to see their GP for further assessment if potential undiagnosed hypertension (systolic blood pressure >160 mmHg), diabetes mellitus (HbA1c >48 mmol/mol), or significant isolated hypercholesterolemia (total-cholesterol >8.0 mmol/l) are observed, as possible continuous medical treatments will be better managed by the GPs. The GPs will be informed by a letter of all negative and positive results and the initiated actions. Additionally in the FISICH-I trial, four further randomizations are performed. In the written invitations to the screening examination two further randomizations are performed;
Power calculations and Randomisations Randomisation will be performed in SPSS by providing each individual a random number from 1-20. Those numbered +16 will be invited to participate in the screening program. Those numbered 17 and 18 will be prebooked, while those numbered 19 and 20 will have to book themselves through web-booking, email or phone. Those with an equal number (18 and 20) will receive supplemental informative pictures of the screening session. In case of positive finding a new random number from 1-4 is given. Those numbered 3 and 4 will be confronted with imaging of their own arterial lesions, whilst others will receive standard information. Those with an equal number (2 and 4) will receive a SMS, e-mail and phone call 3 & 12 months after the consultation. If all groups after randomisations are equally sized,- 182 will only be additionally randomized to be remembered prescription renewal after 3 and 12 months, and 182 will only have been randomized to the standard of booking (Control group for all invited). If 12 months compliance to initiated preventive medication is 66%, then with 0.05 significance level, and 80% power, the smallest difference detectable is 15%, which seems clinical relevant. However, merged analyses adjusting for the other interventions will be performed reducing the smallest detectable difference and reveal potential synergistic combinations. Similar group comparisons will be performed for all randomized interventions. Baseline variables Age, smoking, previous or current stroke, ischemic heart disease, PAD, chronic obstructive pulmonary disease, diabetes, hypertension, use of statins, useof antithrombotics, body mass index, systolic- and diastolic blood pressure, ankle brachial index, marital status, highest educational level, personal- andin house income, psychiatric morbidity defined as any diagnosis and/or use of medications for mental illness, and QoL. Baseline and outcome variables from national registries The CPR number assigned to Danish citizens enables individual-level linkage to multiple nation-wide healthcare and administrative registries which have proved valid. Registry-based information on outpatient visits, hospitals admissions and procedures (The Danish National Patient Registry), relevant prescribed drugs dispensed (The Danish National Prescription Registry), socio economic status etc. (Registries at Statistics Denmark) and primary care service use (National Health Insurance Service Registry) will be obtained. Outcomes The primary outcomes are
Secondary outcome is: 1. QoL, Statistical analysis Baseline characteristics will be analysed using conventional summary statistics. Attendance rates adjusted for invitation layout and booking-method, as well as compliance one year after initiation (def.: received a prescription 9-12 months after the consultation) adjusted for image-confrontation and post-consultation phone call are compared by logistic regression analysis. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Factorial Assignment Intervention Model Description: 2 x factorial design regarding attendance rate to cardiovacular screening Masking: None (Open Label)Primary Purpose: Screening |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE |
5000 | ||||
Original Actual Enrollment ICMJE | Same as current | ||||
Actual Study Completion Date ICMJE | March 31, 2019 | ||||
Actual Primary Completion Date | March 31, 2019 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 60 Years to 65 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Denmark | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03946956 | ||||
Other Study ID Numbers ICMJE | S20160164a | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | Jes Lindholt, Odense University Hospital | ||||
Study Sponsor ICMJE | Odense University Hospital | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE |
|
||||
PRS Account | Odense University Hospital | ||||
Verification Date | May 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |